Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617000641392
Ethics application status
Approved
Date submitted
1/05/2017
Date registered
3/05/2017
Date last updated
13/10/2021
Date data sharing statement initially provided
13/10/2021
Date results information initially provided
13/10/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
Comparative assessment of the absorption of a generic formulation of mesalazine tablet against the innovator mesalazine tablet conducted under fasting conditions in healthy male and female volunteers in a pilot study
Scientific title
A single dose, randomized, blinded, bioequivalence pilot study of a test formulation of mesalazine tablet in a 2 way crossover comparison against the innovator mesalazine tablet conducted under fasting conditions in healthy male and female volunteers
Secondary ID [1] 291816 0
None
Universal Trial Number (UTN)
U1111-1195-1932
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bioequivalence pilot study conducted in healthy volunteers comparing two formulations of mesalazine tablet with no health condition or problem studied.

Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, mezalazine is used for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis. 303055 0
Condition category
Condition code
Oral and Gastrointestinal 302514 302514 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Single dose, crossover study design whereby each participant receives the test formulation of mesalazine oral tablet (1 x 1.2 g) on one occasion and the innovator formulation of mesalazine oral tablet (1 x 1.2 g) on one occasion with each dose seperated by a one week washout period. The intervention for this trial is the test formulation of mesalazine.

No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with the dose).

Participants are required not to eat for 10 hours prior to dosing. Subjects are required to fast for approximately 4 hours after receiving each dose. Bathroom visits will be supervised to ensure no unauthorised water or food intake and for personal safety. Participants will be confined at the Clinical Site for 10 hours prior to dosing to ensure compliance and will be monitored for adverse events for 24 hours after dosing.

Standard meals will be consumed at the Clinical Site with no additional food intake allowed. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site 10 hours prior to dosing.

Pre and post study laboratory tests will be completed to assess the health of participants along with HIV, Hepatitis and drugs of abuse testing.

Each dose will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure the medication has been taken as directed.
Intervention code [1] 297927 0
Treatment: Drugs
Comparator / control treatment
Single dose, crossover pilot study design whereby each participant receives the test formulation of mesalazine (1 x 1.2 g) on one occasion and the innovator formulation of mesalazine (1 x 1.2 g) on one occasion with each dose seperated by a one week washout period. The comparator/control for this trial is the innovator formulation of mesalazine.
Control group
Active

Outcomes
Primary outcome [1] 301926 0
To compare the bioavailability of mesalazine (as summarised by Cmax and AUC) for the formulation. All plasma samples will be assayed for mesalazine using one fully validated LC/MS/MS method. Validation will be conducted to comply with EU and FDA guidelines.
Timepoint [1] 301926 0
0, 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 11, 12, 16, 20, 24, 32, 48, 56 and 72 hours post dosing
Secondary outcome [1] 334287 0
Time to maximum peak concentration (Tmax) will be determined by plasma sample analysis. Tmax will be the time where the maximum concentration occurred in the sample points.
Timepoint [1] 334287 0
0, 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 11, 12, 16, 20, 24, 32, 48, 56 and 72 hours post dosing

Eligibility
Key inclusion criteria
Healthy male and non-pregnant females
Aged between 18 and 55
Non-smoker
BMI between 18 and 30 inclusive
Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
Able to provide written informed consent
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
Concomitant drug therapy of any kind
Sensitivity to the study drug
History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
Females who are pregnant and/or are breastfeeding
Smoker (anyone who has smoked in the last 6 months)
History of alcohol or drug abuse or dependency
Participation in a drug study within 60 days of the start of the study or donated blood in the 60 days preceding the study.
Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All formulations will be labelled as Formulation A and B. The identification of each treatment will only be known to the Managing Director and the Section Head - Trials and Regulatory Affairs.

Each participant will be identified by a 3 digit screening number and a 2 digit subject number. The screening number will be issued once the participant has given written consent to participate in the study and the two digit subject number (randomisation number) after acceptance into the study
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation list will be prepared using a computer program for a balanced two-way crossover design.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Bio-equivalence
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
5/05/2017
Actual
12/05/2017
Date of last participant enrolment
Anticipated
Actual
12/05/2017
Date of last data collection
Anticipated
Actual
23/05/2017
Sample size
Target
12
Accrual to date
Final
10
Recruitment outside Australia
Country [1] 8859 0
New Zealand
State/province [1] 8859 0
Otago

Funding & Sponsors
Funding source category [1] 296318 0
Commercial sector/Industry
Name [1] 296318 0
Southern Cross Pharma Pty Ltd
Country [1] 296318 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Zenith Technology Corp Ltd
Address
156 Frederick St
Dunedin 9016
Country
New Zealand
Secondary sponsor category [1] 295244 0
None
Name [1] 295244 0
Address [1] 295244 0
Country [1] 295244 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 297548 0
Northern A Health and Disability Ethics Committee
Ethics committee address [1] 297548 0
Ministry of Health
Freyberg Building
20 Aitken Street
PO Box 5013
Wellington 6011
Ethics committee country [1] 297548 0
New Zealand
Date submitted for ethics approval [1] 297548 0
12/04/2017
Approval date [1] 297548 0
26/04/2017
Ethics approval number [1] 297548 0
17/NTA/68

Summary
Brief summary
The objective of this pilot study is to evaluate the bioequivalence of the test (new) formulation of 1 x 1.2 g mesalazine tablet against the reference formulation (innovator brand of 1 x 1.2 g mesalazine tablet) following oral administration of a single dose of 1.2 g in healthy male and female subjects under fasting conditions.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 74402 0
Dr Noelyn Hung
Address 74402 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 74402 0
New Zealand
Phone 74402 0
+6434779669
Fax 74402 0
+6434779605
Email 74402 0
[email protected]
Contact person for public queries
Name 74403 0
Mrs Linda Folland
Address 74403 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 74403 0
New Zealand
Phone 74403 0
+6434779669
Fax 74403 0
+6434779605
Email 74403 0
[email protected]
Contact person for scientific queries
Name 74404 0
Dr Cheung-Tak Hung
Address 74404 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 74404 0
New Zealand
Phone 74404 0
+6434779669
Fax 74404 0
+6434779605
Email 74404 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.